Le Lézard
Classified in: Science and technology
Subject: ACC

INVISIO receives the largest order ever, worth SEK 130 million, from a United States Defense Department organization


STOCKHOLM, June 7, 2023 /PRNewswire/ -- INVISIO has received an order worth approximately SEK 130 million for hearing protection and related products under the Racal Acoustics brand. The customer is a branch of the US Department of Defense and the order is the largest in the history of INVISIO Group. The systems will be used in combat vehicles and most of the deliveries will take place during the current year.

The hearing protection systems under the Racal Acoustics brand are mainly used in combat vehicle crewman applications in critical and extremely noisy conditions, which puts high demands both on communication capability and hearing protection functionality.

"This is another impressive victory for INVISIO. There is no doubt that the Racal Acoustics solutions are market-leading in extremely noisy vehicle environments. This order and the two orders received earlier this year, totaling more than SEK 250 million, are clear examples of the increased activity level we are now seeing in the market for heavy military vehicles and in general", says Lars Højgård Hansen, CEO of INVISIO.

For further information, please contact:
Lars Højgård Hansen, CEO, INVISIO
Mobile: + 45 5372 7722 | Email: [email protected]

Michael Peterson, Director Investor Relations & Corporate Communication, INVISIO
mobile: +45 5372 7733 | email: [email protected]

This information is information that INVISIO AB (publ) is obliged to disclose under the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the President/CEO, on June 7, 2023, at 15:20 CEST.

About INVISIO AB (publ)

INVISIO develops and sells advanced communication systems that enable professionals in noisy and mission critical environ­­ments to communicate, protect their hearing and work effectively. The company combines specialist knowledge in acoustics and hearing with broad engineering know-how including in software, materials technology and integration. The company's solutions are marketed under the two brands INVISIO and Racal Acoustics. Sales are via the headquarters in Copenhagen and sales offices in the USA, France, the United Kingdom, Italy and Thailand and via a global network of partners. INVISIO's registered office is in Stockholm and the company is listed on Nasdaq Stockholm (IVSO). Additional information is available on the company's website www.invisio.com.

The following files are available for download:

https://mb.cision.com/Main/17798/3782661/2111976.pdf

INVISIO recieves the largest order ever

 


These press releases may also interest you

at 21:29
HIX.AI, an all-in-one AI writing copilot has officially launched HIX Tutor, a powerful AI homework helper that provides step-by-step solutions to homework problems and exam questions. The homework AI tool is designed to help with all subjects...

at 21:25
A news report from China.org.cn on why did the Chinese accept scientific socialism? The Chinese always have dreamed to make their country a Utopia. In the Confucian classic The Book of Rites, we read, "When the Great Way prevails, the world belongs...

at 21:21
CheolSun Kang corrects his previous early warning announcement of March 14, 2024 to advise he never had ownership or control over Graphizer Inc., as previously set out in the initial announcement, which holds 4,500,000 shares of AGEDB Technology Ltd....

at 21:12
Record Operating Revenues and Net Income: DeFi Technologies recorded its strongest quarter ever, achieving Operating Revenues of C$13.4 million and Operating Net Income of C$5.3 million for Q1 2024.Strategic Advancements and Product Launches: The...

at 21:11
The Honourable Harjit Sajjan, President of the King's Privy Council for Canada, Minister of Emergency Preparedness and Minister responsible for the Pacific Economic Development Agency of Canada, and the Honourable Dan Vandal, Minister of Northern...

at 21:03
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...



News published on and distributed by: